AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Height, spine bone mineral density (BMD), calcaneus BMD, smoking, and number of live births
Number of subjects: 645
Study 1639879 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine syrup B.P. (30 mg/10 ml, q.d.s.)
Number of subjects: 0
Study 1639879 — intervention group
Group type: COMPARATOR
Intervention: Syrup vehicle (placebo)
Number of subjects: 0
Study 6711556 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of maintenance therapy (n = 8)
Number of subjects: 52
Study 6711556 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 months of maintenance therapy (n = 13)
Number of subjects: 52
Study 30836871 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratings of gods as monitoring and punishing
Number of subjects: 2228
Study 30836871 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishing and monitoring gods
Number of subjects: 2228
Study 29175714 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation to the plantar intrinsic foot muscles (PIFMs) from mid-stance to pre-swing using surface electrodes
Number of subjects: 20
Study 29175714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 20
Study 26856909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DHA-PPQ)
Number of subjects: 128
Study 26856909 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 128
Study 23996287 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 44
Study 23996287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22739977 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 268
Study 22739977 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 268
Study 20061026 — intervention group
Group type: EXPERIMENTAL
Intervention: LSA+MPL/TDM/CWS
Number of subjects: 3
Study 20061026 — intervention group
Group type: EXPERIMENTAL
Intervention: LSA+BCG
Number of subjects: 3
Study 20061026 — intervention group
Group type: EXPERIMENTAL
Intervention: LSA+AdjuPrime
Number of subjects: 3
Study 20061026 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study 17890316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet-and-exercise intervention
Number of subjects: 147
Study 17890316 — intervention group
Group type: COMPARATOR
Intervention: Control program
Number of subjects: 147
Study 15199092 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus subtotal nodal irradiation (STNI)
Number of subjects: 0
Study 15199092 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus involved-field radiotherapy (IFRT)
Number of subjects: 0
Study 11535506 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 107
Study 9513099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivoclar‐Vivodent and Orthotyp
Number of subjects: 67
Study 9513099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentsply‐Trublend SLM
Number of subjects: 67
Study 9513099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentsply‐Bioblend IPN
Number of subjects: 67
Study 9513099 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual tooth wear (canine, premolar, molar)
Number of subjects: 67
Study 8071266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (18 sessions of CBT plus desipramine withdrawn at 24 weeks)
Number of subjects: 61
Study 8071266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT) alone (18 sessions)
Number of subjects: 61
Study 8071266 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (16 weeks)
Number of subjects: 61
Study 8071266 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (24 weeks)
Number of subjects: 61
Study 2920585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg every 12 h
Number of subjects: 28
Study 2920585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg every 12 h
Number of subjects: 28
Study 2920585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg every 12 h
Number of subjects: 28
Study 2920585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1084093 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous vaccination with BCG and measles vaccine
Number of subjects: 1000
Study 1084093 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccine alone
Number of subjects: 1000
Study 1084093 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccine alone
Number of subjects: 1000
Study 31812609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Education Program (SEP)
Number of subjects: 210
Study 31812609 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living Program (HLP)
Number of subjects: 210
Study 30606784 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 34
Study 30606784 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 34
Study 28502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-controlled mandibular positioner (FCMP) test
Number of subjects: 202
Study 28502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom oral appliance treatment
Number of subjects: 202
Study 25279818 — intervention group
Group type: EXPERIMENTAL
Intervention: Noribogaine 3 mg
Number of subjects: 36
Study 25279818 — intervention group
Group type: EXPERIMENTAL
Intervention: Noribogaine 10 mg
Number of subjects: 36
Study 25279818 — intervention group
Group type: EXPERIMENTAL
Intervention: Noribogaine 30 mg
Number of subjects: 36
Study 25279818 — intervention group
Group type: EXPERIMENTAL
Intervention: Noribogaine 60 mg
Number of subjects: 36
Study 25279818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24107875 — intervention group
Group type: EXPERIMENTAL
Intervention: Piascledine (300 mg daily for two months, combined with artrosilene 320 mg daily for the first month)
Number of subjects: 0
Study 24107875 — intervention group
Group type: COMPARATOR
Intervention: Artrosilene (NSAIDs, monotherapy)
Number of subjects: 0
Study 20430409 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 trials of hands‐on practice of the pyloroplasty procedure
Number of subjects: 16
Study 20430409 — intervention group
Group type: COMPARATOR
Intervention: No practice (control group)
Number of subjects: 16
Study 19194327 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week Math intervention (n = 28)
Number of subjects: 54
Study 19194327 — intervention group
Group type: COMPARATOR
Intervention: Standard psychoeducational contrast group (n = 26)
Number of subjects: 54
Study 15710002 — intervention group
Group type: EXPERIMENTAL
Intervention: FLCA group (famotidine 20 mg b.d., lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Number of subjects: 177
Study 15710002 — intervention group
Group type: COMPARATOR
Intervention: LCA group (lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Number of subjects: 177
Study 12000375 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 32
Study 12000375 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 32
Study 12000375 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin A
Number of subjects: 32
Study 12000375 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypsin
Number of subjects: 32
Study 12000375 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF)
Number of subjects: 32
Study 12000375 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin
Number of subjects: 32
Study 12000375 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin B
Number of subjects: 32
Study 12000375 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 32
Study 9706928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 25 microg
Number of subjects: 79
Study 9706928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 microg
Number of subjects: 79
Study 9706928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intrathecal neostigmine 12.5 microg and morphine 50 microg
Number of subjects: 79
Study 9706928 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution 0.2 mL
Number of subjects: 79
Study 7882125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybex 6000 isokinetic testing device (ITD)
Number of subjects: 59
Study 7882125 — intervention group
Group type: COMPARATOR
Intervention: ordinary leg extension bench (LEB)
Number of subjects: 59
Study 2118925 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN) for 2 weeks
Number of subjects: 0
Study 2118925 — intervention group
Group type: COMPARATOR
Intervention: Elemental feedings for 2 weeks
Number of subjects: 0
Study 717761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with adrenaline
Number of subjects: 100
Study 717761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline
Number of subjects: 100
Study 717761 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic (control group)
Number of subjects: 100
Study 717761 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine caudal block (control group)
Number of subjects: 100
Study 27749803 — intervention group
Group type: EXPERIMENTAL
Intervention: Clowns (n = 18)
Number of subjects: 105
Study 27749803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dogs (n = 24)
Number of subjects: 105
Study 27749803 — intervention group
Group type: EXPERIMENTAL
Intervention: Musicians (n = 15)
Number of subjects: 105
Study 27749803 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) (N = 48)
Number of subjects: 105
Study 28857595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 3.5 months
Number of subjects: 118
Study 28857595 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group receiving standard medical care for 3.5 months
Number of subjects: 118
Study 26278470 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference-Based Approach (IBA)
Number of subjects: 90
Study 26278470 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90
Study 23575031 — intervention group
Group type: EXPERIMENTAL
Intervention: iQuit system (web-based program and automated tailored text messages)
Number of subjects: 600
Study 23575031 — intervention group
Group type: COMPARATOR
Intervention: usual care (Control)
Number of subjects: 600
Study 21878070 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus ethylmethylhydroxypyridine succinate
Number of subjects: 100
Study 21878070 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 100
Study 19164318 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 36 000 IU
Number of subjects: 122
Study 19164318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 17313998 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of LT
Number of subjects: 59
Study 17313998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 15531626 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy plus usual GP care
Number of subjects: 0
Study 15531626 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care alone
Number of subjects: 0
Study 11557167 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 19
Study 11557167 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 19
Study 11557167 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 0 mg (Control)
Number of subjects: 19
Study 9644751 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for 3 days
Number of subjects: 50
Study 9644751 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 625 mg 3 times a day for 10 days
Number of subjects: 50
Study 9644751 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 50
Study 9644751 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 50
Study 8043072 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in serum cholesterol concentration of 0.6 mmol/l (about 10%)
Number of subjects: 500000
Study 3362276 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate (1,800 mmol/kg H2O)
Number of subjects: 23
Study 3362276 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate (600 mmol/kg H2O)
Number of subjects: 23
Study 3362276 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (850 mmol/kg H2O)
Number of subjects: 23
Study 31950167 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps program (volunteering at elementary schools)
Number of subjects: 336
Study 31950167 — intervention group
Group type: COMPARATOR
Intervention: Low-activity control group
Number of subjects: 336
Study 30337273 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS857 (0.06 mg/kg intravenously once a week for 12 weeks)
Number of subjects: 27
Study 30337273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30337273 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS857
Number of subjects: 27
Study 30337273 — intervention group
Group type: COMPARATOR
Intervention: BVS857 and Placebo
Number of subjects: 27
Study 27571927 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with bevacizumab
Number of subjects: 0
Study 27571927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 27571927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Atezolizumab + Bevacizumab)
Number of subjects: 0
Study 25677278 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational pamphlets written at a grade 5 reading level
Number of subjects: 179
Study 25677278 — intervention group
Group type: COMPARATOR
Intervention: Educational pamphlets written at a grade 10 reading level
Number of subjects: 179
Study 23272986 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness therapy (mindfulness‐based stress reduction and some cognitive behavioral therapy elements for BDS)
Number of subjects: 119
Study 23272986 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (2‐hour specialist medical care and brief cognitive behavioral therapy for BDS)
Number of subjects: 119
Study 20679587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 18
Study 20679587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19018213 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment (COPE)
Number of subjects: 246
Study 19018213 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 246
Study 16170119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 140
Study 16170119 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 140
Study 11788429 — intervention group
Group type: COMPARATOR
Intervention: Intravenous terbutaline
Number of subjects: 0
Study 11788429 — intervention group
Group type: COMPARATOR
Intervention: Drug-free state
Number of subjects: 0
Study 10027483 — intervention group
Group type: EXPERIMENTAL
Intervention: Zadaxin (SciClone)
Number of subjects: 9
Study 10027483 — intervention group
Group type: EXPERIMENTAL
Intervention: Timosina (Sclavo)
Number of subjects: 9
Study 10027483 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (Tal-HLR; Hoffmann La Roche)
Number of subjects: 9
Study 7577405 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg for children 6-10 years and 50 mg for children 10-14 years)
Number of subjects: 45
Study 7577405 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (20 micrograms for all age groups)
Number of subjects: 45
Study 7577405 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline/Desmopressin combination
Number of subjects: 45
Study 7577405 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline/Desmopressin
Number of subjects: 45
Study 2196771 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 180 or 240 mg/day
Number of subjects: 601
Study 2196771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study 6108711 — intervention group
Group type: EXPERIMENTAL
Intervention: PRD‐92 (mast cell stabilizer)
Number of subjects: 43
Study 6108711 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (control)
Number of subjects: 43
Study 6108711 — intervention group
Group type: EXPERIMENTAL
Intervention: PRD‐92
Number of subjects: 43
Study 31136052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641
Study 28923809 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted facilitation
Number of subjects: 8
Study 28923809 — intervention group
Group type: COMPARATOR
Intervention: Generalized QI facilitation
Number of subjects: 8
Study 26130352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic reduction
Number of subjects: 74
Study 26130352 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic reduction
Number of subjects: 74
Study 23447078 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (250 mg acipimox tablet)
Number of subjects: 20
Study 23447078 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (250 mg acipimox tablet)
Number of subjects: 20
Study 20461438 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant, ondansetron, and dexamethasone
Number of subjects: 0
Study 20461438 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron and dexamethasone (active control)
Number of subjects: 0
Study 19301086 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg, 1 h prior to incision, re-administered once daily on postoperative days 1-4)
Number of subjects: 55
Study 19301086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 17261562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice water immersion (5+/−1 degrees C)
Number of subjects: 40
Study 17261562 — intervention group
Group type: COMPARATOR
Intervention: Tepid water immersion (24 degrees C)
Number of subjects: 40
Study 14984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available herbal preparation STW 5
Number of subjects: 208
Study 14984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Research herbal preparation STW 5‐II
Number of subjects: 208
Study 14984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter candytuft mono‐extract
Number of subjects: 208
Study 14984373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 11317478 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg cerivastatin daily for 7 days
Number of subjects: 49
Study 11317478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10726721 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan/12.5 mg hydrochlorothiazide (L50H12.5C)
Number of subjects: 24
Study 10726721 — intervention group
Group type: COMPARATOR
Intervention: 100 mg losartan monotherapy (L100)
Number of subjects: 24
Study 10726721 — intervention group
Group type: COMPARATOR
Intervention: 50 mg losartan
Number of subjects: 24
Study 8873542 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 24
Study 8873542 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 24
Study 8873542 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 24
Study 1567188 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical recombinant alpha-2 interferon gel, applied four times daily for four days
Number of subjects: 387
Study 1567188 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied four times daily for four days
Number of subjects: 387
Study 3926040 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic physicians palpation of thoracic paravertebral soft tissue (T1-T8)
Number of subjects: 62
Study 3926040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 62
Study 3926040 — intervention group
Group type: COMPARATOR
Intervention: Excluded group (no intervention specified)
Number of subjects: 62
Study 29734823 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplement (SQ-LNS) 20 g/d
Number of subjects: 1320
Study 29734823 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) until delivery, then placebo until 6 months postpartum
Number of subjects: 1320
Study 29734823 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMNs) until 6 months postpartum
Number of subjects: 1320
Study 27139495 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI) - one ultrasound guided injection around the affected tendons and advice on tendon care.
Number of subjects: 201
Study 27139495 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-administered load modification and exercise intervention - education about load modification and a home-based and supervised exercise programme.
Number of subjects: 201
Study 27139495 — intervention group
Group type: COMPARATOR
Intervention: Wait and see approach - basic tendon care advice and reassurance in a single session by a trial physiotherapist.
Number of subjects: 201
Study 24887686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d for 1 week)
Number of subjects: 35
Study 24887686 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 35
Study 24887686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d for 1 week) with meloxicam
Number of subjects: 35
Study 22635021 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 100
Study 22635021 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate
Number of subjects: 100
Study 20010420 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training in hypoxemic events (Group 1)
Number of subjects: 21